Navigation Links
Savara Closes Series A Financing Round
Date:6/9/2009

- Funds Raised Will Be Used to Expand Technology into New Pulmonary Markets -

AUSTIN, Texas, June 9 /PRNewswire/ -- Savara Pharmaceuticals, a biotechnology inhalation drug delivery company, today announced that it has closed its Series A financing round.

The majority of Savara's existing investors participated in the round, which was made up of biotechnology industry veterans and successful business leaders. Savara will utilize the funds to continue development of its NanoCluster technology in the dry powder therapeutics market and expand into nebulizer and propellant markets.

"I'm excited that we exceeded our entire Series A fund raising goal in just a few weeks," said Rob Neville, Savara's Executive Chairman. "The funds from our seed round allowed us to validate our technology across multiple drug classes, which led to several partnerships with large pharmaceutical companies. We've assembled a world class team and are ready to pursue the numerous opportunities ahead of us."

Savara has the option to complete a second tranche of the Series A round later this year if additional funds are needed.

The key parameter to improving the efficacy of pulmonary products depends on being able to dial-in particles sizes in the range of one to three microns. The Savara NanoCluster technology has this capability without the need for novel excipients and benefits from a highly efficient manufacturing process. These NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung.

About Savara

Savara Pharmaceuticals, (www.savarapharma.com) develops next generation pulmonary drug delivery solutions using its NanoCluster formulation technology. Dry powder and nebulizer-based medicines are formulated directly from active drug ingredients, requiring no carrier particles and little or no excipients. The aerodynamics of NanoCluster formulations are fully customizable from one to seven microns enabling high drug concentrations at specific regions of the lung, independent of the rate or depth of breath. Savara expects that NanoCluster's unique features will produce numerous patient benefits including reduced dosage, enhanced efficacy, improved safety and increased tolerability, as well as greater patient convenience. Savara's NanoCluster technology is currently available for evaluation and licensing.

CONTACT: Ian M. Stone for Savara Pharmaceuticals, +1-619-528-2220, ian.stone@russopartnersllc.com


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical Closes $12.65 million Unit Offering
2. Swine Flu Closes Three Schools in NYC
3. Swine Flu Closes 3 Schools in NYC
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. ASA May Day - Stung By Exposure of Watergate-like Public Record Deletions, American Society of Anesthesiologists Closes Access to Website Newsletter
6. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
7. PhotoThera Closes $50 Million Financing, Announces New President and Chief Executive Officer
8. ProAssurance Closes PICA Transaction
9. Conseco Closes Amendment to Credit Facility
10. ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
11. GetWellNetwork Closes $10 Million Financing, Eight Hospitals Choose PatientLife System(R) for Unparalleled Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
Breaking Medicine Technology: